Chikungunya Virus –Like Particle Vaccine

To the Editor The chikungunya virus –like particle (CHIKV VLP) vaccine described in a recent article by Dr Chen and colleagues is one of several chikungunya vaccines that have completed either phase 1 or preclinical phases. The phase 2 randomized clinical trial reported focuses on pertinent clinical questions of safety and tolerabil ity of the vaccine in a chikungunya-endemic area. The trial enrolled healthy adults aged 18 through 60 years who had tested negative for chikungunya virus IgM/IgG and randomized them to receive 20 μg of the vaccine or a placebo. Both safety and tolerability were demonstrated.
Source: JAMA - Category: General Medicine Source Type: research